BG
MLNT

Bellevue Group’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Bellevue Group’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,420
Closed -$507K – 136
2017
Q4 		$507K Buy
+6,420
New +$475K 0.05% 124

Other funds holding MLNT

OH
Oikos Holdings New York $422M AUM 13.79% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Bellevue Group's MLNT Position: Q1 2018 in Review

Bellevue Group sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2018, closing a stake of 6,420 shares — an estimated $507K sold.

Bellevue Group first reported a position in MLNT in Q4 2017 and held it in 1 quarter. The position peaked at $507K in Q4 2017. 83 funds tracked by Wall St. Rank hold MLNT as of Q1 2018.

  • Bellevue Group reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Bellevue Group sold 6,420 Melinta Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $507K.
  • Bellevue Group first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Bellevue Group's Melinta Therapeutics, Inc. Common Stock position peaked at $507K in Q4 2017.
  • 83 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Bellevue Group's 13F filing for Q1 2018, filed 9 May 2018.